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1362Objectives: To compare the therapeutic efficacy of recombinant human brain natriuretic peptide and prosta-
glandin E1 in the treatment of pulmonary hypertension after mitral valve replacement.
Methods: Sixty patients with postoperative pulmonary hypertension were divided randomly into 3 groups that
received saline, prostaglandin E1, and natriuretic peptide infusions for 12 hours each. The hemodynamics data
were monitored consecutively, and the levels of thromboxane A2 and cyclic guanosine monophosphate were
detected pretreatment, after treatment, and 1 week after surgery.
Results: The arterial pressure, pulmonary arterial pressure, and pulmonary capillary wedge pressure decreased
1 hour after prostaglandin E1 treatment and rebounded after treatment discontinuation. The pulmonary arterial
pressure and pulmonary capillary wedge pressure in the natriuretic peptide group decreased 3 hours after treat-
ment; pulmonary arterial pressure decreased less than that of the prostaglandin group, and there was no evidence
of hemodynamic rebound after treatment discontinuation. The natriuretic peptide had no significant effects on
arterial pressure. In both the prostaglandin and natriuretic peptide groups, cyclic guanosine monophosphate
increased after the treatment, which was even higher in the latter group. Prostaglandin E1 could lead to the
decrease of thromboxane A2, which was not seen in the natriuretic peptide group.
Conclusions: Both brain natriuretic peptide and prostaglandin E1 can effectively reduce pulmonary hypertension;
however, natriuretic peptide has a slower andmilder efficacy. The effects of these 2 drugs in reducing the pulmonary
arterial pressure may be mediated through different pathways. (J Thorac Cardiovasc Surg 2014;147:1362-7)Most patients who have mitral valve disease combined with
pulmonary hypertension suffer persistent pulmonary hyper-
tension after their valve replacement1 because of their
previous pulmonary arteriole fibrosis and the release of in-
flammatory factors caused by surgical trauma and cardio-
pulmonary bypass.2,3 Pulmonary hypertension can
increase afterload of the right heart chamber, causing
cardiac events and affecting survival after surgery4,5; thus
correct selection of effective drugs to reduce pulmonary
arterial pressure (PAP) has important clinical significance.
Brain natriuretic peptide (BNP) is a polypeptide secreted
by the ventricles that can resist cardiac volume and
pressure load and regulate vascular tone. In recent years,
recombinant human BNP (rhBNP) has been used in
clinical practice, but its PAP-lowering effect after cardiac
surgery has no exact statistical data. Considering that its ac-
tion time and metabolic time are similar to prostaglandin E1e Chest Clinical Research Center,a Tianjin Medical University, Tianjin,
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The Journal of Thoracic and Cardiovascular Sur(PGE1), which is used commonly in clinical practice at pre-
sent,6,7 we compared the pharmacodynamics of the 2 drugs
in the short term after surgery. A number of studies have
shown that thromboxane A2 (TXA2) and cyclic
guanosine monophosphate (cGMP) play important roles
in the regulation of pulmonary vasoconstriction.8,9 In this
study, the mechanisms of the 2 drugs in lowering PAP
were compared further by detecting the concentration
changes in TXA2 and cGMP before and after treatment.METHODS
Study Design and Patient Selection
Patients who received mitral valve replacement (MVR) during cardio-
pulmonary bypass in the Cardiac Center of Tianjin Chest Hospital from
March 2011 to May 2012 were included in this study. After surgery, a total
of 60 patients with a mean PAP (MPAP) of 25 mm Hg or higher (measured
by using the CCOmbo Swan-Ganz catheter; Edwards LifeSciences, Irvine,
Calif) were enrolled randomly in this study. In particular, patients with
unstable hemodynamics (systolic arterial pressure<60mmHg, pulmonary
artery systolic pressure>70 mmHg, or low cardiac output syndrome) who
needed multiple drugs for treatment were ruled out.
After the surgery, the patients were transferred to the intensive care unit
(ICU), assisted by ventilators, and received dopamine and other vasoactive
drugs to maintain their basic vital signs in a stable state. All the enrolled
patients were divided randomly into 3 groups: the control group, in which
patients received a continuous infusion of saline at 5 mL/h for 12 hours;
the rhBNP group, in which patients first received an intravenous
injection of rhBNP at 2 mg/kg, and then received a continuous infusion
at 0.01 mg/kg/min for 12 hours; and the PGE1 group, in which patients
received a continuous infusion of PGE1 at 30 ng/kg/min for 12 hours.gery c April 2014
FIGURE 1. Design of the study. TXA2, Thromboxane A2; cGMP, cyclic
guanosine monophosphate; PGE1, prostaglandin E1; MVR, mitral valve
replacement; PH, pulmonary hypertension; rhBNP, recombinant human
brain natriuretic peptide.
FIGURE 2. A, P<.05 compared with the T1 group. B, P<.05 compared
with the T2 group. C, P<.05 compared with the T3 group. D, P< .05
compared with the T4 group. E, P< .05 compared with the T5 group.
Abbreviations and Acronyms
BNP ¼ brain natriuretic peptide
cGMP ¼ cyclic guanosine monophosphate
ELISA ¼ enzyme-linked immunosorbent assay
ICU ¼ intensive care unit
MAP ¼ mean radial arterial pressure
MPAP ¼ mean pulmonary arterial pressure
MVR ¼ mitral valve replacement
PAP ¼ pulmonary arterial pressure
PCWP ¼ pulmonary capillary wedge pressure
PGE1 ¼ prostaglandin E1
PVRI ¼ pulmonary vascular resistance index
rhBNP ¼ recombinant human brain natriuretic
peptide
TXA2 ¼ thromboxane A2
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MThe mean radial arterial pressure (MAP), MPAP, pulmonary capillary
wedge pressure (PCWP), cardiac output index, and pulmonary vascular
resistance index (PVRI) data were measured with a Philips IntelliVue
mp40 monitor (Philips Medical Systems, Irvine, Calif) at the following
time points: before treatment, at 1, 3, 6, and 12 hours after treatment,
and 2 hours after treatment discontinuation. Whole blood samples were
collected from the peripheral venous blood of the patients before treatment,
2 hours after discontinuation of the drugs, as well as 1 week after surgery
(Figure 1). The enzyme-linked immunosorbent assay (ELISA) method was
used to detect the cGMP and TXA2 concentrations. The Human cGMP
ELISA and Human TXA2 ELISA kits were manufactured by Shanghai
Blue-Gene Biotech Co, Ltd (Shanghai, China).
All the groups were double-blinded, and no nitric oxide, PDE inhibitors,
or similar drugs were given to patients in the study. The study was
terminated in case of any severe hypotension, severe pulmonary hyperten-
sion, heart failure, and so forth, and other drugs should be used to treat these
conditions accordingly. The Medical Ethics Committee of Tianjin and the
Institutional Review Board of Tianjin Medical University approved the
study, and all patients signed written informed consent before study
initiation.
Statistical Analysis
All data were tested via a one-sample Kolmogorov-Smirnov test for
normality. If the P value was greater than .10 the data were considered to
be normal distributions, which were expressed as the mean  standard
deviation, whereas non-normal distributions were expressed as the median
 quartile.
For normal distributions, the metrologic data within the same group at
different time points were analyzed via one-way analysis of variance
followed by the Student–Newman–Keuls test to compare the means of
independent groups. Non-normally distributed data were analyzed via
the rank-sum test.
The Pearson correlation was used to examine the extent of the
correlations between related parameters. A P value of less than .05 was
considered statistically different.
*P<.05 compared with the control group. #P<.05 compared with the
PGE1 group. T1, After surgery and pretreatment; T2, 1 hour after treat-
ment; T3, 3 hours after treatment; T4, 6 hours after treatment; T5, 12 hours
after treatment; T6, 2 hours after treatment discontinuation; PGE1, prosta-
glandin E1; rhBNP, recombinant human brain natriuretic peptide; MAP,
mean radial arterial pressure.RESULTS
Patient Characteristics
There were no significant differences among the 3 groups
in the preoperative demographics and intraoperativeThe Journal of Thoracic and Carvariables including cardiopulmonary bypass time, cross-
clamping time, mitral valve gradient after replacement,
and so forth (P > .05). No significant differences were
observed in the inotrope score (dopamine dose [mg/kg/
min] þ dobutamine dose [mg/kg/min] þ 1003 epinephrine
dose [mg/kg/min] þ 1003 norepinephrine dose [mg/kg/
min]) in the ICU (P > .05), whereas the postoperative
ventilator-assisted duration in the PGE1 group was shorter
than in the control groups (P<.05) (Table 1).
All the nurses and doctors followed the procedures
strictly and obtained the hemodynamic and laboratory
data punctually. One patient in the control group had an
MPAP greater than 70 mm Hg and signs of right heartdiovascular Surgery c Volume 147, Number 4 1363
FIGURE 3. A, P<.05 compared with the T1 group. B, P<.05 compared
with the T2 group. C, P<.05 compared with the T3 group. D, P<.05
compared with the T4 group. E, P< .05 compared with the T5 group.
*P<.05 compared with the control group. #P<.05 compared with the
PGE1 group. T1, After surgery and pretreatment; T2, 1 hour after treat-
ment; T3, 3 hours after treatment; T4, 6 hours after treatment; T5, 12 hours
after treatment; T6, 2 hours after treatment discontinuation; PGE1, prosta-
glandin E1; rhBNP, recombinant human brain natriuretic peptide; MPAP,
mean pulmonary arterial pressure.
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with nitric oxide inhalation, milrinone, and PGE1 infusion.
The laboratory data from this patient were excluded. The
other 59 patients finished the study and there were no
missing data points.Homodynamic Data
MAP data. Intragroup comparison. The MAP of the
PGE1 group had decreased since 1 hour after treatment
(79.3  11.4 to 71.2  12.5 mm Hg) (P < .05), and
recovered to the initial level at 6 hours after treatment
(76.8  11.3 mm Hg) (P> .05). However, it tended to
rebound after treatment discontinuation (78.2  9.6 to
84.3  13.4 mm Hg) (P < .05). No similar variations
in the MAP were observed in the control group and the
rhBNP group.
Intergroup comparison. During 1 to 3 hours after treat-
ment, the level of MAP in the PGE1 group was lower
than in the control group and the rhBNP group (1 hour:
71.2  12.5 vs 78.8  9.8, 81.3  8.1 mm Hg; 3 hours:
73.8 10.6 vs 82.0 8.9, 79.1 9.3 mm Hg, respectively)
(P<.05). During 6 to 12 hours after treatment, there were
no significant differences among the 3 groups in MAPTABLE 1. Patient characteristics
Groups Sex, M/F Age, y Hypertension, Y/N Diabetes, Y/N
Control group 11/9 56  7 3/17 1/19
PGE1 group 9/11 56  9 2/18 0/20
rhBNP group 13/7 57  7 3/17 0/20
M, Male; F, female; Y, yes;N, no;CPB, cardiopulmonary bypass;MV, mitral valve; ICU, inte
peptide. *P<.05 compared with the control group.
1364 The Journal of Thoracic and Cardiovascular Sur(P>.05). The level of MAP in the PGE1 group was higher
than those in the other 2 groups at 2 hours after treatment
discontinuation (84.3  13.4 vs 80.4  10.3, 78.0  12.2
mm Hg, respectively) (P<.05) (Figure 2).
MPAP data. Intragroup comparison. The MPAP of the
PGE1 group decreased drastically at 1 hour after treatment
(32.7 7.6 to 21.9 11.4 mm Hg) (P<.05), and increased
slightly at 3 hours after treatment (3 hours: 23.8 10.1 mm
Hg) (P<.05), however, it was still lower than the MPAP
level at pretreatment (P< .05). It tended to rebound at 2
hours after treatment discontinuation (27.9  8.0 mm Hg)
(P< .05). The MPAP of the rhBNP group decreased at 3
hours after treatment (33.1  6.1 to 27.6  6.4 mm Hg)
(P< .05), and stayed stable until 2 hours after treatment
discontinuation (P>.05). There was no significant change
during the trial in the control group (P>.05).
Intergroup comparison. The level of MPAP in the PGE1
group was lower than that in the rhBNP group at 1, 3, and
6 hours after treatment (1 hour: 21.9  11.4 vs 30.8  8.9
mmHg; 3 hours: 23.8 10.1 vs 27.6 6.4 mmHg; 6 hours:
24.8  9.7 vs 26.9  8.5 mm Hg, respectively) (P<.05).
There were no significant differences between the PGE1
group and the rhBNP group at 12 hours after treatment
(25.5  8.8 vs 25.4  9.2 mm Hg, respectively) (P>.05)
(Figure 3).
PCWP data. Intragroup comparison. The PCWP of the
PGE1 group decreased 1 hour after treatment (21.6  8.7
to 13.5  5.6 mm Hg) (P< .05), and increased slightly
3 hours after treatment (16.3  6.1) (P<.05), then stayed
stable at this level. It returned to the pretreatment level
2 hours after treatment discontinuation (P > .05). The
PCWP of the rhBNP group had decreased since 3 hours af-
ter treatment (20.7  5.8 to 17.7  4.2 mm Hg) (P<.05),
without significant fluctuation until the end of the trial
(P>.05). There was no significant change during the trial
in the control group (P>.05).
Intergroup comparison. After the onset of the 2 drugs, the
level of PCWP in the PGE1 group was similar to the
rhBNP group (3 hours: 16.3  6.1 vs 17.7  4.2 mm
Hg; 6 hours: 16.2  6.9 vs 17.0  4.1 mm Hg; 12 hours:
17.0  7.0 vs 16.6  6.5 mm Hg, respectively) (P>.05)
(Figure 4).
Cardiac output index data. Intragroup comparison. No
significant fluctuations were observed during the trial in
all 3 groups (P>.05).Smoking, Y/N Atrial fibrillation, Y/N
Stenosis/regurgitation/
combination
11/9 13/7 4/5/11
10/10 14/6 5/5/10
11/9 15/5 7/2/11
nsive care unit;PGE1, prostaglandin E1; rhBNP, recombinant human brain natriuretic
gery c April 2014
FIGURE 4. A, P<.05 compared with the T1 group. B, P<.05 compared
with the T2 group. C, P<.05 compared with the T3 group. D, P<.05
compared with the T4 group. E, P< .05 compared with the T5 group.
*P<.05 compared with the control group. #P<.05 compared with the
PGE1 group. T1, After surgery and pretreatment; T2, 1 hour after treat-
ment; T3, 3 hours after treatment; T4, 6 hours after treatment; T5, 12 hours
after treatment; T6, 2 hours after treatment discontinuation; PGE1, prosta-
glandin E1; rhBNP, recombinant human brain natriuretic peptide;
PCWP, pulmonary capillary wedge pressure.
FIGURE 5. T1, After surgery and pretreatment; T2, 1 hour after treat-
ment; T3, 3 hours after treatment; T4, 6 hours after treatment; T5, 12 hours
after treatment; T6, 2 hours after treatment discontinuation; PGE1, prosta-
glandin E1; rhBNP, recombinant human brain natriuretic peptide;
CI, cardic output index.
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observed at each time point among the 3 groups (P>.05)
(Figure 5).
PVRI data. Intragroup comparison. The PVRI of the
PGE1 group decreased drastically 1 hour after treatment
(231.7  114.2 to 163.9  120.6 dynes/s/cm5/m2)
(P < .05), then stayed stable at this level. It tended to
rebound 2 hours after treatment discontinuation (219.5 
47.8 dynes/s/cm5/m2) (P< .05). The PVRI of the rhBNP
group decreased 1 hour after treatment (245.3  40.7 to
210.7  51.0 dynes/s/cm5/m2) (P< .05), and decreased
further 3 hours after treatment (186.5  55.5 dynes/s/cm5/
m2) (P<.05), then stayed stable until the end of the trial
(P>.05). There was no significant change during the trial
in the control group (P>.05).
Intergroup comparison. The level of PVRI in the rhBNP
group was lower than the control group but higher than
the PGE1 group at 1 and 3 hours after treatment
(P< .05). There were no significant differences between
the PGE1 group and the rhBNP group at 6 and 12 hours after
treatment (P>.05), and both groups were higher than the
control group during this time (P<.05). The level of the
rhBNP group was lower than that of the PGE1 group and
the control group at 2 hours after treatment discontinuation
(P<.05) (Figure 6).Cholesterol
level, mmol/L
CPB time,
min
Cross-clamping
time, min
Intraoperative
blood loss M
4.78  1.42 112  33 58  13 278  57
4.46  1.22 121  54 62  19 293  70
4.57  1.77 117  37 56  16 288  64
TABLE 1. Continued
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TXA2 data. Intragroup comparison. In the control group,
the TXA2 level decreased 1 week after surgery (P<.05),
whereas there were no significant changes in the perioper-
ative period (P>.05). In the PGE1 group the TXA2 level
after treatment was lower than that of pretreatment
(P< .05), and it decreased further 1 week after surgery
(P< .05). In the rhBNP group no significant change was
observed before and after treatment (P> .05), however,
the TXA2 level decreased at 1 week after surgery
(P< .05).
Intergroup comparison. There were no significant differ-
ences among the 3 groups in the TXA2 level at pretreatment
and 1 week after surgery (P>.05). The level of the PGE1
group was lower than those of the control group and the
rhBNP group after treatment (P<.05) (Table 2).
cGMP data. Intragroup comparison. In the control
group the cGMP level increased 1 week after surgery
(P< .05), whereas there were no significant changes in
the perioperative period (P>.05). In the PGE1 group the
cGMP level increased after treatment (P < .05), and it
increased further 1 week after surgery (P< .05). In the
rhBNP group the cGMP level increased drastically after
treatment (P<.05). At 1 week after surgery it decreased,
but was still higher compared with pretreatment levels
(P<.05) (Table 3).
Intergroup comparison. There were no significant differ-
ences among the 3 groups in the cGMP level at pretreat-
ment and 1 week after surgery (P > .05). The level ofPostoperative mean
V gradient, mm Hg
Postoperative ventilator-
assisted time, h
Inotrope score
in the ICU
6.7  3.4 46  25 6.4  2.1
7.2  3.1 37  29* 6.9  2.7
6.9  3.6 42  30 6.1  2.5
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FIGURE 6. A, P<.05 compared with the T1 group. B, P<.05 compared
with the T2 group. C, P<.05 compared with the T3 group. D, P<.05
compared with the T4 group. E, P< .05 compared with the T5 group.
*P<.05 compared with the control group. #P<.05 compared with the
PGE1 group. T1, After surgery and pretreatment; T2, 1 hour after treat-
ment; T3, 3 hours after treatment; T4, 6 hours after treatment; T5, 12 hours
after treatment; T6, 2 hours after treatment discontinuation; PGE1, prosta-
glandin E1; rhBNP, recombinant human brain natriuretic peptide; PVRI,
pulmonary vascular resistance index.
TABLE 3. cGMP data (pg/mL)
Groups T1 T2 T3
Control group 10.7  7.6 11.1  8.4 21.1  15.2*,y
PGE1 group 11.3  8.3 18.5  13.3*,z 22.5  18.4*,y
rhBNP group 9.9  8.7 33.8  20.1*,z,x 23.6  19.9*,y
T1, Pretreatment after surgery; T2, 2 hours after discontinuation of the drugs; T3,
1 week after surgery; PGE1, prostaglandin E1; rhBNP, recombinant human brain
natriuretic peptide. *P<.05 compared with the T1 group. yP<.05 compared with
the T2 group. zP<.05 compared with the control group. xP<.05 compared with
the PGE1 group.
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but lower than that of the rhBNP group after treatment
(P< .05).
The cGMP concentration was correlated negatively with
MPAP after treatment (r ¼ 0.63, P<.05). However, no
significant correlation was observed between the cGMP
concentration and MPAP at pretreatment. The TXA2 con-
centration had no significant correlation with MPAP either.DISCUSSION
Pulmonary hypertension caused by mitral stenosis or
mitral incompetence belongs to type 2 pulmonary
hypertension (left heart system disease–induced pulmo-
nary hypertension). According to the European Society
of Cardiology/European Respiratory Society guidelines10
published in 2009, in the short-term therapy of postopera-
tive pulmonary hypertension, prostaglandin was listed as a
grade I-A drug to treat the nonvasoreactive pulmonary
hypertension in stages III and IV patients (World Health
Organization-functional class); the PAP-lowering effect
of rhBNP, however, was not mentioned. Our study indi-
cated that the PAP-lowering action of rhBNP was slower
and milder compared with PGE1. Moreover, we found
that PGE1 reduced the PAP and simultaneously causedTABLE 2. TXA2 data (pg/mL)
Groups T1 T2 T3
Control group 442  265 418  295 280  104*,y
PGE1 group 455  220 309  199*,z 268  114*,y
rhBNP group 424  269 402  281x 288  166*,y
T1, Pretreatment after surgery;T2, 2 hours after discontinuation of the drugs;T3, 1week
after surgery; PGE1, prostaglandin E1; rhBNP, recombinant human brain natriuretic
peptide. *P<.05 compared with the T1 group. yP<.05 compared with the T2 group.
zP<.05 compared with the control group. xP<.05 compared with the PGE1 group.
1366 The Journal of Thoracic and Cardiovascular Surthe decrease in systemic vascular resistance, however,
the PAP tended to rebound after the treatment discontinu-
ation. This behavior was not observed in the rhBNP group.
Thus, the result suggested that rhBNP is suitable to treat
patients with hemodynamic instability, especially low
blood pressure, and PGE-1 has obvious effects in control-
ling the acute pulmonary hypertension crisis. At present,
no similar studies have been conducted in which
continuous hemodynamic monitoring is performed during
rhBNP treatment. The results from the current study may
provide a reference for further studies about the rhBNP
action time. In terms of the effects on decreasing PAP,
Michaels et al11 proposed that the infusion of rhBNP for
30 minutes could reduce the MPAP by 29% and PVRI
by 35% for patients with postcapillary pulmonary hyper-
tension (MPAP  25 mm Hg; PCWP> 15 mm Hg) at a
rest stage. In the current study, most of the patients also
had postcapillary pulmonary hypertension, but the efficacy
was lower than the data reported by Michaels et al.11 The
discrepancy may be related to the pulmonary vascular
ischemia-reperfusion injury after the cardiopulmonary
bypass surgery, leading to a decrease of the reactivity.2
Although PGE1 and rhBNP could decrease PAP and
PVRI, the drugs had no significant effect on cardiac output
index. It might be owing to multiple factors such as blood
volume, heart rhythm, and so forth.
The decreased TXA2 and increased cGMP concentra-
tions after the application of PGE1 suggest that the vaso-
dilatating effects may be mediated through different
pathways. Reports about the effects of PGE1 on reducing
the TXA2 level are available.8 Fortier et al12 also pro-
posed that prostacyclin could increase cyclic adenosine
monophosphate levels in Landrace swine. Therefore,
studies with a large scale of cases in human beings are
required to confirm the direct effect of PGE1 on the
cGMP pathway. The present study results indicated that
rhBNP only affects the guanosine triphosphate–cGMP
pathway, but the increase of cGMP was higher than that
of PGE1, suggesting that the guanylate cyclase receptors
are more sensitive to BNP compared with PGE1 (the gua-
nylate cyclase can catalyze guanosine triphosphate to
convert guanosine triphosphate into cGMP). Compared
with the study performed by Khush et al,13 the decreasegery c April 2014
Chen et al Perioperative Managementof MPAP is smaller with the application of rhBNP,
whereas the increase of cGMP is similar (in the study
results obtained by Khush et al,13 patients with postcapil-
lary pulmonary hypertension at a resting state received
continuous infusion of rhBNP for 30 minutes and their
MPAP decreased by 29 mm Hg  11 mm Hg, whereas
the cGMP in the peripheral blood increased by 341%).
Therefore, pulmonary vascular injury after cardiopulmo-
nary bypass can reduce the activity of the lower-level
pathways of cGMP. However, it has a weak effect on
the synthesis of cGMP after receiving BNP stimulation.
As a result, the concentrations of cGMP and TXA2 in
the PGE1 and rhBNP groups had no significant
differences compared with the control group 1 week
after treatment, which indicated that although the
short-term application of PGE1 and rhBNP after sur-
gery can reduce the PAP and shorten the postoperative
ventilator-assisted duration, the continuous PAP control
with a long-term oral medication is still necessary if pa-
tients continue to have serious postoperative pulmonary
hypertension.Limitations
To review, almost all the patients in this study received
different doses of dopamine or diuretics in the ICU, which
inevitably affected the hemodynamics and caused bias in
data collection. Because of the small sample size, the effect
of rhBNP on pulmonary hypertension was not shown accu-
rately in this study, which probably can be clarified further
with a larger sample size.CONCLUSIONS
RhBNP effectively can reduce the PAP after anMVR sur-
gery. However, it works slower and more mildly compared
with PGE1 for different mechanisms. Both rhBNP and
PGE1 have no long-term effects owing to their shortThe Journal of Thoracic and Carmetabolic duration. The long-term PAP-lowering applica-
tion is still required for MVR patients after discharge.References
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